Angiogenesis and anti-angiogenesis in hematological malignancies

Journal of Hematotherapy and Stem Cell Research

Volumn 12, Issue 1, 2003, Pages 11-22

  Ribatti, Domenico ^a,c   Vacca, Angelo ^a   Dammacco, Franco ^a   English, Denis ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Human Anatomy ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 4; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ENDOSTATIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 1BETA; LAMININ; MATRIX METALLOPROTEINASE; MITOMYCIN C; PACLITAXEL; SCATTER FACTOR; TEGAFUR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; B CELL LYMPHOMA; BIRTH DEFECT; BLOOD VESSEL; BONE MARROW; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CARDIOVASCULAR SYSTEM; CELL INFILTRATION; CELL INTERACTION; CELL STIMULATION; CHORIOALLANTOIS; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; DRUG ACTIVITY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HUMAN; LYMPHOID TISSUE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAST CELL; MICROVASCULATURE; MULTIPLE MYELOMA; NEUTROPHIL; OSTEOCLAST; PARAPROTEINEMIA; PHOCOMELIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STROMA CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UMBILICAL VEIN; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHICK EMBRYO; CLINICAL TRIALS; DISEASE PROGRESSION; ERYTHROPOIETIN; HUMANS; LEUKEMIA; LYMPHOMA; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS;

EID: 0037295157     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581603321210091     Document Type: Review

References (98)

1. Sabin FR. (1917). Preliminary note on the differentiation of angioblasts and the method by which they produce blood vessels, blood plasma and red blood cells as seen in the living chick. Anat Rec 13:199-204 (reprinted in J Hematother Stem Cell Res (2002) 11:5-8).
2. Sabin FR. (1917). Preliminary note on the differentiation of angioblasts and the method by which they produce blood vessels, blood plasma and red blood cells as seen in the living chick. Anat Rec 13:199-204 (reprinted in J Hematother Stem Cell Res (2002) 11:5-8).
3. Murray PDF. (1934). The development in vitro of blood of the chick embryo. Proc R Soc B 111:497-524.
4. Choi K. (2002). The hemangioblast: a common progenitor of hematopoietic and endothelial cells. J Hematother Stem Cell Res 11:91-102.
5. Mikkola HKA and SH Orkin. (2002). The research for the hemangioblast. J Hematother Stem Cell Res 11:9-18.
6. Yancopoulos GD, S Davis, NW Gale, JS Rudge, IS Wiegand and J Holash. (2002). Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
7. Palis J, RJ Chan, A Koniski, R Patel, M Starr and MC Yoder. (2001). Spatial and temporal emergence of high proliferative potential haematopoietic precursors during murine embryogenesis. Proc Natl Acad Sci USA 98:4528-4533.
8. Choi K, M Kennedy, A Kazarov, JC Papadimitriou and G Keller. (1998). A common precursor for hematopoietic and endothelial cells. Development 125:725-732.
9. Lu L, SJ Wang and R Aurebach. (1996). In vitro and in vivo differentiation into B cells, T cells and myeloid cells of primitive yolk sac hematopoietic precursor cells expanded > 100 fold by coculture with a clonal yolk sac endothelial cell line. Proc Natl Acad Sci USA 93:14782-14787.
10. Orkin SH and LI Zon. (2002). Hematopoiesis and stem cells: plasticity versus developmental heterogeneity. Nature Immunol 3:323-328.
11. Risau W and I Flamme. (1995). Vasculogenesis. Annu Rev Cell Dev Biol 11:73-91.
12. Ribatti D, A Vacca, B Nico, R Ria and F Dammacco. (2002). Cross-talk between hematopoiesis and angiogenesis signaling pathways. Curr Mol Med 2:537-543.
13. Pelletier L, J Regnard, A Fellmann and P Chabord. (2000). An in vitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokine. Lab Invest 80:501-511.
14. Ribatti D, A Vacca, L Roncali and F Dammacco. (2000). Hematopoiesis and angiogenesis: a link between two apparently independent processes. J Hematother Stem Cell Res 9(1):13-19.
15. Bussolino F, JM Wang, P De Filippi, F Turrini, F Sanavio, CJS Edgell, M Aglietta, P Arese and A Mantovani. (1989). Granulocyte and granulocyte-macrophage colony stimulating factor induce human endothelial cells to migrate and proliferate. Nature 337:471-473.
16. Valdembri D, G Serini, A Vacca, D Ribatti and F Bussolino. (2002). In vivo activation of JAK-2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J 16:225-227.
17. Ribatti D, A Vacca, L Roncali and F Dammacco. (1996). The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol 40:1189-1197.
18. Ribatti D, B Nico, A Vacca, L Roncali, PH Burri and V Djonov. (2002). Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat Rec 264:317-324.
19. Chen H, AT Treeweeke, DC West, KJ Till, JC Cawley, M Zuzel and CH Toth. (2000). In vitro and in vivo production of vascular endothelial growth factor in chronic lymphocytic leukemia cells. Blood 96:3181-3187.
20. English DE, Z Welch, AT Kovala, K Harvey, OV Volpert and JG Garcia. (2000). Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 14:2255-2265.
21. English DE, AT Kovala, Z Welch, KA Harvey, RA Siddiqui, DN Bringley and JG Garcia. (1999). Induction of endothelial cell chemotaxis by sphingosine-1-phosphate and stabilization of endothelial monolayer permeability by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 8:627-634.
22. Mandala SM. (2000). Shingosine-1-phosphate phosphatase. Prostaglandins 64:143-156.
23. Carlini RG, AA Reyes and M Rothstein. (1995). Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745.
24. Ribatti D, M Presta, A Vacca, R Ria, R Giuliani, P Dell'Era, B Nico, L Roncali and F Dammacco. (1999). Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636.
25. Folkman J. (1995). Clinical applications of research on angiogenesis. New Engl J Med 333:1757-1763.
26. Mignatti P and DB Rifkin. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195.
27. Aznavoorian S, AN Murphy, WG Stetler-Stevenson and LA Liotta. (1993). Molecular aspects of tumor cell invasion and metastasis. Cancer 72:1368-1383.
28. Hanahan D and J Folkman. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
29. Folkman J. (1990). What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4-6.
30. Bertolini F, P Mancuso, A Gobbi and G Pruneri. (2000). The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol 28:993-1000.
31. Mangi MH and AC Newland. (2000). Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 111:43-51.
32. Perez-Atayde AR, SE Sallan, U Tedrow, S Connors, EN Allured and J Folkman. (1997). Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphocytic leukemia. Am J Pathol 150:815-821.
33. Aguayo AR, H Kantarajian, T Manshouri, C Gidel, E Estey, D Thomas, C Koller, Z Estov, S O'Brien, M Keating, M Freing, E Freireich and M Albitar. (2000). Angiogenesis in acute and chronic leukemia and myelodysplastic syndromes. Blood 96:2240-2245.
34. Aguayo AR, E Estey, H Kantarajian, T Manshouri, C Gidel, M Keating, F Giles, Z Estrow, B Barlogie and M Albitar. (1999). Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94:3717-3721.
35. Hussong JW, GM Rodgers and PJ Shami. (2000). Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95:390-313.
36. Padro T, S Ruiz, R Bieker, H Burger, M Steins, J Kienast, T Buchner, WE Berdel and RM Mesters. (2000). Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95:2637-2644.
37. Molica S, C Vitelli, D Levato, GM Gandolfo and V Liso. (1999). Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukemia. Br J Haematol 107:605-610.
38. Molica S, A Vacca, D Ribatti, A Cuneo, F Cavazzini, D Levato, G Vitelli, L Tucci, AM Roccaro and F Dammacco. (2002). Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100:3344-3351.
39. Kini AR, NE Kay and LC Peterson. (2000). Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 14:1414-1418.
40. Bellamy WT, L Richter, Y Frutiger and TM Grogan. (1999). Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733.
41. Dias S, K Hattori, Z Zhu, B Heissig, M Chay, W Lane, Y Wu, A Chadbrun, E Hyjek, M Gill, DJ Hicklin, L Witte, MA Moore and S Raffi. (2000). Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511-521.
42. Konig A, T Menzel, S Lynes, L Wrazel, A Rosen, A Al-Katib, E Raveche and JL Gabrilove. (1997). Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11:258-265.
43. Lundberg LG, P Lerner, R Sundelin, R Rogres, J Folkman and J Palmblad. (2000). Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol 157:15-19.
44. Vacca A, D Ribatti, L Roncali, G Ranieri, G Serio, F Silvestris and F Dammacco. (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503-508.
45. Vacca A, D Ribatti, M Presta, M Minischetti, M Iurlaro, R Ria, A Albini, F Bussolino and F Dammacco. (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-3073.
46. Di Raimondo FD, MP Azzaro, GA Palumbo, S Bagnato, G Giustolisi, PM Floridia, G Sortino and R Giustolisi. (2000). Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85:800-805.
47. Iwasaki T, T Hamano, T Ogata, N Hashimoto, M Kitano and E Kakishita. (2002). Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 116:796-802.
48. Soubrier M, J Dubost, AF Serre, JM Ristori, B Sauvezie, P Cathebras, JC Piette, A Chapman, FJ Authier and RK Gherardi. (1997). Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthrit Rheum 40:786-787.
49. Ribatti D, A Vacca, B Nico, M Fanelli, L Roncali and F Dammacco. (1996). Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 56:45-53.
50. Bellamy WT. (2001). Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 28:551-559.
51. Stewart M, K Talks, R Leek, H Turley, F Pezzella, H Harris and K Gatter. (2002). Expression of angiogenic factors and hypoxia inducible factors HIF-1, HIF-2 and CAIX in non Hodgkin's lymphoma. Histopathology 40:253-260.
52. Salven P, L Teerenhovi and H Joensun. (1999). A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94:3334-3339.
53. Salven P, A Orpona, L Teerenhovi and H Joensun. (2000). Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non Hodgkin's lymphoma: a single-institution study of 200 patients. Blood 96:3712-3718.
54. Bertolini F, M Paolucci, S Peccatori, S Cinieri, A Agazzi, PF Ferrucci, E Cocorocchio, A Goldhirsch and G Martinelli. (1999). Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 106:504-509.
55. Foss HD, I Araujo, G Demel, H Klotzbach, M Hummel and H Stein. (1997). Expression of vascular endothelial growth factor in lymphoma and Castelman's disease. J Pathol 183:44-50.
56. Coussens LM and Z Web. (1996). Matrix metalloproteinases and the development of cancer. Chem Biol 3:895-904.
57. Johnson LL, R Dyer and DJ Hupe. (1998). Matrix metalloproteinases. Curr Opin Chem Biol 4:466-471.
58. Vacca A, D Ribatti, M Iurlaro, A Albini, M Minischetti, F Bussolino, A Pellegrino, R Ria, M Rusnati, M Presta, V Vincenti, MG Persico and F Dammacco. (1998). Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis and angiogenesis. Int J Clin Lab Res 28:55-68.
59. Barilleè S, C Aknoundi, M Collette, MP Mellerin, MJ Rapp, JL Harrousseau, R Bataille and M Amiot. (1997). Metalloproteinases in multiple myeloma: production of matrix metalloproteinase 9 (MMP-9), activation of pro-MMP-2, and induction of MMP-1 by myeloma cells. Blood 90:1649-1655.
60. Hayashibara T, Y Yamada, Y Onimaru, C Tsutsumi, S Nakayama, N Mori, T Miyanishi, S Kamihira, M Tomonaga and T Maita. (2002). Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukemia cell invasion. Br J Haematol 116:94-102.
61. Taichman RS, MJ Reilly and SG Emerson. (1996). Human osteoblasts support human hematopoietic progenitor cells in in vitro bone marrow cultures. Blood 88:518-524.
62. Dankbar B, T Padro, R Leo, B Feldmann, M Kropff, RM Mesters, H Serve, WE Berdel and J Kienast. (2000). Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95:2630-2636.
63. Fiedler W, V Graeven, S Ergun, S Verago, N Kilic, M Stockschladeer and DK Hossfeld. (1997). Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89:1870-1875.
64. Solanilla A, A Elandaloussi, C Grosset, P Duchez, MD Mossalayi, FX Mahon, J Reiffers, G Marit and J Ripoche. (2000). Differential effect of interferon alpha on chronic myelogenous leukaemia and normal haemopoietic progenitors in a stromal cell co-culture context: role of the flt3 ligand. Br J Haematol 109:392-387.
65. Allouche AR, F Bayard, S Clamens, G Fillolla, P Sie and F Amalric. (1995). Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia 9:77-86.
66. Fusetti L, G Pruneri, A Gobbi, C Rabascio, N Carboni, F Peccatori, G Martinelli and F Bertolini. (2000). Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 60:2927-2534.
67. Klein B, X Zhang and Z Lu. (1995). Interleukin-6 in human multiple myeloma. Blood 85:863-872.
68. Bataille R and JL Harousseau. (1997). Multiple myeloma. N Engl J Med 336:1657-1664.
69. Klein B, X Zhang, M Jourdan, J Content, F Houssian, L Aarden, M Piechaezyk and M Bataille. (1989). Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by IL-6. Blood 73:517-526.
70. Deckers MM, M Karperien, C van der Bent, T Yamashita, SE Papapoulos and CW Lowik. (2000). Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141:1667-1674.
71. Nakagawa M, T Kaneda, T Arawaka, S Morita, T Sato, T Yomada, K Hanada, M Kumegawa and Y Hakeda. (2000). Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161-164.
72. Bellamy WT, L Richter, D Sirjani, C Roxas, B Glinsmann-Gibson, Y Frutiger, TM Grogan and AF List. (2001). Vascular endothelial growth factor (VEGF) is an autocrine promoter of abnormal localized immature precursors (ALIP) and leukemia progenitor formation in myelodysplastic syndromes. Blood 97:1427-1434.
73. Ribatti D, A Vacca, B Nico, F Quondamatteo, R Ria, M Minischetti, A Marzullo, R Herken, L Roncali and F Dammacco. (1999). Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79:451-455.
74. Ribatti D, B Nico, A Vacca, A Marzullo, N Calvi, L Roncali and F Dammacco. (1998). Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br J Cancer 77:1900-1906.
75. Ribatti D, A Vacca, A Marzullo, B Nico, R Ria, L Roncali and F Dammacco. (2000). Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer 85:171-175.
76. Fukushima N, H Sato, M Sano and O Tokunaga. (2001). Angiogenesis and mast cells in non Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 42:709-720.
77. Vacca A, D Ribatti, L Ruco, F Giacchetta, B Nico, F Quondamatteo, R Ria, M Iurlaro and F Dammacco. (1999). Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphoma. Br J Cancer 79:965-970.
78. Talks KL and AL Harris. (2000). Current status of antiangiogenic factors. Br J Haematol 109:477-489.
79. Richardson P, T Hideshima and K Anderson. (2002). Thalidomide: emerging role in cancer medicine. Annu Rev Med 53:629-657.
80. D'Amato RJ, ES Laughnan, E Flynn and J Folkman. (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085.
81. Kenyon BM, F Browne and RJ D'Amato. (1997). Effects of thalidomide and related metabolities in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978.
82. Singhal S, J Metha, R Desijan, D Ayers, P Robertson, P Eddleman, N Munshi, E Anaissie, C Wilson, M Dhodhapakar, J Zeldis and B Barlogie. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 341:1565-1571.
83. Juliusson G, F Celsing, I Turesson, S Lenhoff, M Adriansson and C Malm. (2000). Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89-96.
84. Kneller A, P Raanani, I Hardan, A Avigdor, I Vi, M Berkowicz and I Ben-Bassat. (2000). Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 108:391-393.
85. Pini M, A Baraldi, D Pietrasanta, B Allione, L Depaoli, F Salvi and A Levis. (2000). Low-dose thalidomide in the treatment of refractory myeloma. Haematologica 85:1111-1112.
86. Rajkumar SV, R Fonseca, A Dispenzieri, MQ Lacy, JA Lust, TE Witzig, RA Kyle, MA Gertz and PR Greipp. (2000). Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proc 75:97-901.
87. Zomas A, N Anagnostopoulos and MA Dimopoulos. (2000). Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 25:1319-1320.
88. Gupta D, SP Treon, Y Shima, T Hideshima, K Podar, YT Tai, B Lin, S Lentzsch, FE Davies, D Chauhan, RL Schlossman, P Richardson, P Ralph, L Wu, F Dayvandi, G Muller, DI Stirling and KC Anderson. (2001). Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950-1961.
89. Vacca A, M Iurlaro, D Ribatti, M Minischetti, B Nico, R Ria, A Pellegrino and F Dammacco. (1999). Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143-4155.
90. Kerbel KS, A Viloria-Petit, G Klement and J Rak. (2000). 'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36:1248-1257.
91. Scappaticci FA, R Smith, A Pathak, D Schloss, B Lum, Y Cao, F Johnson, EG Engleman and GP Nolan. (2001). Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 3:186-196.
92. Bertolini F, L Fugetti, P Mancuso, A Gobbi, C Corsini, PF Ferrucci, G Martinelli and G Pruneri. (2000). Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin's lymphoma. Blood 96:282-287.
93. Quesada JR, EM Hersh, J Manning, J Keuben, M Keating, E Schnipper, L Itri and JU Guterman. (1986). Treatment of hairy cell leukemia with recombinant alpha interferon. Blood 68:493-497.
94. Di Raimondo F, E Fichera, MP Azzaro, F Stagno, GA Palumbo and R Giustolisi. (2000). Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients (abstract 4825). Blood 96(suppl 1):253b.
95. Pepper MS, JD Vassalli, JW Wilks, RL Schweigerer, L Orci and R Montesano. (1994). Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 55:419-434.
96. White CW, HM Sondheimer, EC Crouch, H Wilson and LL Fan. (1989). Treatment of pulmonary hemangiomatosis with recombinant interferon α-2a. N Engl J Med 320:1197-1200.
97. Mitsuyasu RT. (1991). Interferon α in the treatment of AIDS-related Kaposi's sarcoma. Br J Haematol 79:69-73.
98. Kaban LB, JB Mulliken, RA Ezekowitz, D Ebb, PS Smith and J Folkman. (1989). Antiangiogenic therapy of a giant cell tumor of the mandible with interferon α-2a. Pediatrics 103:1145-1149.